Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuti
Julie Yoo will make investments out of the firm's bio fund.
Almost exactly two years ago, the venture firm Andreessen Horowitz took the wraps off a $200 million “biofund” that aimed to invest at the intersection of biology and engineering and was b
Andreessen Horowitz is making an even bigger push into healthcare IT, bringing aboard serial entrepreneur Jorge Conde as a general partner. Conde has spent the last 15 years working largely in genomic